These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma. Cornelison TL; Baker TR; Piver MS; Driscoll DL Gynecol Oncol; 1995 Nov; 59(2):243-8. PubMed ID: 7590480 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Ayoub J; Audet-Lapointe P; Méthot Y; Hanley J; Beaulieu R; Chemaly R; Cormier A; Déry JP; Drouin P; Gauthier P Gynecol Oncol; 1988 Oct; 31(2):327-37. PubMed ID: 2971597 [TBL] [Abstract][Full Text] [Related]
5. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate. Kline RC; Freedman RS; Jones LA; Atkinson EN Cancer Treat Rep; 1987 Mar; 71(3):327-8. PubMed ID: 2949831 [No Abstract] [Full Text] [Related]
6. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Whitney CW; Brunetto VL; Zaino RJ; Lentz SS; Sorosky J; Armstrong DK; Lee RB; Gynecol Oncol; 2004 Jan; 92(1):4-9. PubMed ID: 14751130 [TBL] [Abstract][Full Text] [Related]
7. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study. Bafaloukos D; Aravantinos G; Samonis G; Katsifis G; Bakoyiannis C; Skarlos D; Kosmidis P Oncology; 1999 Apr; 56(3):198-201. PubMed ID: 10202274 [TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay. Stratton JA; Mannel RS; Rettenmaier MA; Berman ML; DiSaia PJ Gynecol Oncol; 1989 Jan; 32(1):55-9. PubMed ID: 2535831 [TBL] [Abstract][Full Text] [Related]
9. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA; Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666 [TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458 [TBL] [Abstract][Full Text] [Related]
11. Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Carlson JA; Allegra JC; Day TG; Wittliff JL Am J Obstet Gynecol; 1984 May; 149(2):149-53. PubMed ID: 6232850 [TBL] [Abstract][Full Text] [Related]
13. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. Hardy JR; Powles TJ; Judson IR; Sinnett HD; Ashley SE; Coombes RC; Ellin CL Eur J Cancer; 1990; 26(7):824-7. PubMed ID: 2145904 [TBL] [Abstract][Full Text] [Related]
14. Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. Hoffman MS; Roberts WS; Cavanagh D; Praphat H; Solomon P; Lyman GH Gynecol Oncol; 1989 Oct; 35(1):75-7. PubMed ID: 2477317 [TBL] [Abstract][Full Text] [Related]
15. [Results of hormone and chemotherapy of patients with cancer of the corpus uteri]. Ploch E Nowotwory; 1985; 35(3):255-61. PubMed ID: 4088901 [No Abstract] [Full Text] [Related]
16. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma. Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570 [TBL] [Abstract][Full Text] [Related]
17. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications]. Mauriac L; Durand M; Bonichon F; Chauvergne J Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203 [TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study. Pierga JY; Dieras V; Paraiso D; Dorval T; Palangie T; Beuzeboc P; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P Gynecol Oncol; 1996 Jan; 60(1):59-63. PubMed ID: 8557229 [TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: a preliminary study. Cohen CJ; Deppe G; Bruckner HW Obstet Gynecol; 1977 Oct; 50(4):415-7. PubMed ID: 904803 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma. Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]